- PT
- |
- EN
Graduated from the Bahiana School of Medicine and Public Health. Residency in Internal Medicine at Hospital Ipiranga and in Hematology and Hemotherapy at Santa Casa de São Paulo. Former fellow of the Cancer Research Center – University Clinical Hospital of Salamanca, Spain. MSc and PhD from Santa Casa de Misericórdia de São Paulo. Permanent professor of the Postgraduate Program in Clinical and Translational Research FIOCRUZ/BA. Head of the Hematology and Hemotherapy unit at the University Hospital – UFBA. Hematologist at Clínica CEHON – Oncologia D’Or. Coordinator of the Integrated Center for the Treatment of Multiple Myeloma – CTM – Hospital São Rafael/Rede D’Or.
Keywords: multiple myeloma; gammopathies; new drugs; immunomodulators
EDUCATION
PhD in Health Sciences, Faculty of Medical Sciences, Santa Casa de São Paulo
Residency in Hematology and Hemotherapy at Santa Casa de Misericórdia de São Paulo
Fellowship at the Cancer Research Center - University Clinical Hospital of Salamanca, Spain
INVESTIGATION AREAS
Hematology
ADITIONAL INFORMATION
AWARDS AND HONORS
Member of the International Myeloma Working Group
Member of the International Myeloma Society
Member of the Brazilian Myeloma Group (GBRAM)
Member of the Brazilian Association of Hematology, Hemotherapy and Cell Therapy
Specialist title in Hematology and Hemotherapy, Brazilian Society of Hematology and Hemotherapy
Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med. 2021 Jul 1;385(1):46-58. PMID: 34192431.
doi: 10.1056/NEJMoa2028631
Crusoé EQ, Pimenta FCF, Maiolino A, Castro NS, Pei H, Trufelli D, Fernandez M, Herriot LB. Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma. Hematol Transfus Cell Ther. 2021 Oct-Dec;43(4):417-423. Epub 2020 Sep 14. PMID: 32967807; PMCID: PMC8573022.
doi: 10.1016/j.htct.2020.07.005
Pessoa de Magalhães Filho RJ, Crusoe E, Riva E, Bujan W, Conte G, Navarro Cabrera JR, Garcia DK, Vega GQ, Macias J, Oliveros Alvear JW, Royg M, Neves LA, Lopez Dopico JL, Espino G, Ortiz DR, Socarra Z, Fantl D, Ruiz-Arguelles GJ, Maiolino A, Hungria VTM, Harousseau JL, Durie B. Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries. Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):e43-e50. Epub 2018 Aug 29. PMID: 30297171.
doi: 10.1016/j.clml.2018.08.005
Hungria VT, Crusoé EQ, Maiolino A, Bittencourt R, Fantl D, Maciel JF, Pessoa de Magalhaes RJ, Almeida MS, Cury P, Hisgashi F, Peres AL, Chiattone CS. Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible. Ann Hematol. 2016 Jan;95(2):271-8. Epub 2015 Oct 30. PMID: 26518211.
doi: 10.1007/s00277-015-2537-2
Ocio EM, Vilanova D, Atadja P, Maiso P, Crusoe E, Fernández-Lázaro D, Garayoa M, San-Segundo L, Hernández-Iglesias T, de Alava E, Shao W, Yao YM, Pandiella A, San-Miguel JF. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica. 2010 May;95(5):794-803. Epub 2009 Nov 30. PMID: 19951978; PMCID: PMC2864386.
doi: 10.3324/haematol.2009.015495
